Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
The successful candidate will play an integral role in the development, generation, and manipulation of mouse embryonic stem cells to generate cancer models for use in drug development. The candidate will learn a wide array of new techniques and cutting edge technologies to assist our growing team and collaborative work environment.
Please forward resumes to Careers@aveopharma.com
AVEO is an Equal Employment Opportunity employer that values the strength diversity brings to the workplace.
AVEO Pharmaceuticals does not accept unsolicited resumes from any third-party recruiters, agencies or individuals. Any such third party recruiters, agencies or individuals seeking to work with AVEO Pharmaceuticals must first contact the staffing group at firstname.lastname@example.org. Only approved staffing vendors will be allowed to provide services to AVEO Pharmaceuticals. Unsolicited resumes will be deemed the property of AVEO Pharmaceuticals to follow up with as it sees applicable and no fee will be paid in the event the candidate is hired as a result of the referral or by other means. Submission of unsolicited resumes does not create any implied obligation on the part of AVEO.
AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development that both increases the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com .